Undervalued Stocks
CRMD is currently part of our Undervalued Stocks screen, meaning it meets strict valuation and quality criteria
CORMEDIX INC (CRMD) Stock Price & Overview
NASDAQ:CRMD • US21900C3088
Current stock price
7.58 USD
+0.19 (+2.57%)
At close:
7.6 USD
+0.02 (+0.26%)
After Hours:
The current stock price of CRMD is 7.58 USD. Today CRMD is up by 2.57%. In the past month the price increased by 21.28%. In the past year, price decreased by -16.7%.
CRMD Key Statistics
52-Week Range6.125 - 17.43
Current CRMD stock price positioned within its 52-week range.
1-Month Range6.2751 - 7.705
Current CRMD stock price positioned within its 1-month range.
- Market Cap
- 599.199M
- P/E
- 3.75
- Fwd P/E
- 8.95
- EPS (TTM)
- 2.02
- Dividend Yield
- N/A
CRMD Stock Performance
Today
+2.57%
1 Week
+3.55%
1 Month
+21.28%
3 Months
+4.26%
Longer-term
6 Months -32.14%
1 Year -16.70%
2 Years +44.24%
3 Years +53.44%
5 Years -12.27%
10 Years -63.73%
CRMD Stock Chart
CRMD Stock Screens
CRMD currently appears in the following ChartMill screener lists.
High Free Cash Flow Stocks
CRMD is currently part of our High Free Cash Flow Stocks screen, indicating it generates strong cash flows relative to its price.
Fastest Growing Stocks
CRMD is part of our fastest growing stocks screen, indicating it has high EPS and sales growth.
Revenue Growth Leaders
CRMD is part of our revenue growth leaders stock screen, indicating it has strong recent and multi-year revenue growth.
CRMD Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to CRMD. When comparing the yearly performance of all stocks, CRMD is a bad performer in the overall market: 78.25% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
CRMD Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to CRMD. CRMD has an average financial health and profitability rating.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
CRMD Earnings
On March 5, 2026 CRMD reported an EPS of 0.18 and a revenue of 128.62M. The company missed EPS expectations (-78.38% surprise) and missed revenue expectations (-0.73% surprise).
Next Earnings DateMay 7, 2026
Last Earnings DateMar 5, 2026
PeriodQ4 / 2025
EPS Reported$0.18
Revenue Reported128.615M
EPS Surprise -78.38%
Revenue Surprise -0.73%
CRMD Forecast & Estimates
13 analysts have analysed CRMD and the average price target is 14.86 USD. This implies a price increase of 96.08% is expected in the next year compared to the current price of 7.58.
For the next year, analysts expect an EPS growth of -58.05% and a revenue growth -1.16% for CRMD
Analysts
Analysts83.08
Price Target14.86 (96.04%)
EPS Next Y-58.05%
Revenue Next Year-1.16%
CRMD Groups
Sector & Classification
CRMD Financial Highlights
Over the last trailing twelve months CRMD reported a non-GAAP Earnings per Share(EPS) of 2.02. The EPS increased by 712.12% compared to the year before.
Income Statements
Revenue(TTM)311.71M
Net Income(TTM)163.06M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 52.31% | ||
| ROA | 19.74% | ||
| ROE | 40.23% | ||
| Debt/Equity | 0.36 |
Chartmill High Growth Momentum
EPS Q2Q%-18.18%
Sales Q2Q%312.11%
EPS 1Y (TTM)712.12%
Revenue 1Y (TTM)617.03%
CRMD Ownership
Ownership
Inst Owners55.66%
Shares79.05M
Float72.74M
Ins Owners7.98%
Short Float %21.7%
Short Ratio10.24
CRMD Competitors/Peers
The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 26.31 | 869.14B | ||
| JNJ | JOHNSON & JOHNSON | 18.19 | 555.642B | ||
| MRK | MERCK & CO. INC. | 23 | 289.223B | ||
| PFE | PFIZER INC | 9.21 | 156.544B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.34 | 120.728B | ||
| ZTS | ZOETIS INC | 17.35 | 51.606B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.54 | 28.443B | ||
| VTRS | VIATRIS INC | 5.96 | 17.315B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.51 | 11.825B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.651B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.206B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.087B | ||
| CORT | CORCEPT THERAPEUTICS INC | 85.4 | 4.929B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CRMD
Company Profile
CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company is headquartered in Berkeley Heights, New Jersey and currently employs 191 full-time employees. The company went IPO on 2010-03-25. The firm is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The firm is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The firm is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.
Company Info
IPO: 2010-03-25
CORMEDIX INC
300 Connell Drive, Suite 4200
Berkeley Heights NEW JERSEY 07922 US
CEO: Khoso Baluch
Employees: 191
Phone: 13026365400
CORMEDIX INC / CRMD FAQ
What does CRMD do?
CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company is headquartered in Berkeley Heights, New Jersey and currently employs 191 full-time employees. The company went IPO on 2010-03-25. The firm is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The firm is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The firm is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.
Can you provide the latest stock price for CORMEDIX INC?
The current stock price of CRMD is 7.58 USD. The price increased by 2.57% in the last trading session.
Does CRMD stock pay dividends?
CRMD does not pay a dividend.
How is the ChartMill rating for CORMEDIX INC?
CRMD has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
What is the Price/Earnings (PE) ratio of CORMEDIX INC (CRMD)?
The PE ratio for CORMEDIX INC (CRMD) is 3.75. This is based on the reported non-GAAP earnings per share of 2.02 and the current share price of 7.58 USD.
What is the outstanding short interest for CORMEDIX INC?
The outstanding short interest for CORMEDIX INC (CRMD) is 21.7% of its float.